ArticleNature communications2025
EP300 deficiency leads to chronic replication stress mediated by defective replication fork protection.
Angelica Barreto-Galvez, Mrunmai Niljikar, Julia Elizabeth Gagliardi, Carolina Plasencia Guzman, Ranran Zhang, Vasudha Kumar, Aastha Juwarwala, Archana Pradeep, Ankit Saxena, Cristina Montagna and 9 more
Abstract read
In one paragraphArticle in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
19 authors.
Angelica Barreto-Galvez *Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Julia Elizabeth GagliardiRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Carolina Plasencia GuzmanRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Ranran ZhangRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Vasudha KumarRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Archana PradeepRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Ankit SaxenaRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Cristina MontagnaRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Jeannine GerhardtDepartment of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA.
Jian CaoRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Keisuke KataokaDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Funding
Project 4: The BRCA Network in Medulloblastoma Responses to Replication StressP01CA250957 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI GANESAN, SHRIDAR · 2021 to 2025
$11.3MRole of PALB2 in the DNA Damage Response and Cancer SuppressionR01CA138804 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI XIA, BING · 2009 to 2024
$5.5MReprogramming myogenic regulatory factors in RMS to promote differentiation and halt growthR01CA275187 · NCI · UNIVERSITY OF COLORADO DENVER · PI Kristin Artinger, Heide L. Ford · 2023 to 2026
$2.8MEpigenetic Alterations and Targeted Therapies in North American ATLLR01CA266847 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Bihui Hilda Ye · 2023 to 2026
$2.1MDissecting high-risk cell states in neuroblastomaR37CA286444 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Adam David Durbin · 2024 to 2026
$1.8MRegulation of DNA replication kinetics by BRCA2 after DNA damageR01CA262227 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI XIA, BING · 2021 to 2025
$1.7MEnvironmental factors and compounds affecting the genomic stability in haploinsufficient BRCA1 cells.R01ES034733 · NIEHS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Jeannine Gerhardt · 2023 to 2026
$1.5MRepetitive sequences causing genomic instability and cell dysfunctionR35GM152228 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Jeannine Gerhardt · 2024 to 2026
$1.3MTargeting EP300, a selective dependency in neuroblastomaK08CA245251 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI DURBIN, ADAM DAVID · 2020 to 2024
$1.3MThe multifaceted role of the Fanconi anemia tumor suppressor pathway in facilitating DNA replicationR00HL136870 · NHLBI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI MADIREDDY, ADVAITHA · 2018 to 2020
$900kCenter for Strategic Scientific Initiatives, National Cancer Institute (NCI Center for Strategic Scientific Initiatives) K08CA245251NCI NIH HHS K08 CA245251NCI NIH HHS P01 CA250957NCI NIH HHS R01 CA138804NCI NIH HHS R01 CA262227NCI NIH HHS R01 CA266847NCI NIH HHS R01 CA275187NCI NIH HHS R37 CA286444NHLBI NIH HHS R00 HL136870NIEHS NIH HHS R01 ES034733NIGMS NIH HHS R35 GM152228U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P01250957-9485U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA138804U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA262227U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA266847U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R00HL136870U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (NIEHS) R01ES034733
6 · The paper itselfAbstract
Mutations in the global transcriptional activator EP300/KAT3B are being reported in aggressive malignancies. However, the mechanistic contribution of EP300 dysregulation to cancer is currently unknown. While EP300 has been implicated in regulating cell cycle and DNA replication, the role of EP300 in maintaining replication fork integrity has not been studied. Here, using EP300-mutated adult T-cell leukemia/lymphoma cells and an EP300-selective degrader, we reveal that EP300 loss leads to pronounced dysregulations in DNA replication dynamics and persistent genomic instability. Aberrant DNA replication in EP300-mutated cells is characterized by elevated replication origin firing due to replisome pausing. EP300 deficiency results in a prominent defect in fork protection resulting in the accumulation of single-stranded DNA gaps. Importantly, we find that the loss of EP300 results in decreased expression of BRCA2 protein leading to sensitivity to treatments that are cytotoxic to BRCA-deficient cancers. Overall, we demonstrate that EP300-mutated cells recapitulate features of BRCA-deficient cancers.
Indexed as
DNA ReplicationE1A-Associated p300 ProteinBRCA2 ProteinCell Line, TumorGenomic InstabilityHumansMutationReplication OriginBRCA2 ProteinBRCA2 protein, humanE1A-Associated p300 ProteinEP300 protein, human
Identifiers
PMID41354653
PMCPMC12800293
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390